Abstract
The nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase, NOX) enzyme family catalyzes the production of reactive oxygen species (ROS). ROS have functional roles in cell cycling and signal transduction but their excessive production results in oxidative stress which is believed to have pathological consequences. Oxidative stress in the intestinal tract is considered a major factor contributing to the pathogenesis and progression of inflammatory bowel disease (IBD), as recent data suggest a positive correlation between upregulated NOX and gastrointestinal inflammation. Moreover, expression of certain NOX gene variants has been shown to affect the susceptibility of an individual to develop IBD. As current treatments for IBD are not entirely effective, the pharmacological inhibition of NOX is an unexplored avenue that could provide a potential therapeutic target for the treatment of this disease.
Keywords: Inflammatory bowel disease (IBD), nicotinamide adenine dinucleotide phosphate oxidase (NADPH), nitric oxide (NO), reactive oxygen species (ROS).
Current Medicinal Chemistry
Title:NADPH Oxidases and Inflammatory Bowel Disease
Volume: 22 Issue: 17
Author(s): Giang Lam, Vasso Apostolopoulos, Anthony Zulli and Kulmira Nurgali
Affiliation:
Keywords: Inflammatory bowel disease (IBD), nicotinamide adenine dinucleotide phosphate oxidase (NADPH), nitric oxide (NO), reactive oxygen species (ROS).
Abstract: The nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase, NOX) enzyme family catalyzes the production of reactive oxygen species (ROS). ROS have functional roles in cell cycling and signal transduction but their excessive production results in oxidative stress which is believed to have pathological consequences. Oxidative stress in the intestinal tract is considered a major factor contributing to the pathogenesis and progression of inflammatory bowel disease (IBD), as recent data suggest a positive correlation between upregulated NOX and gastrointestinal inflammation. Moreover, expression of certain NOX gene variants has been shown to affect the susceptibility of an individual to develop IBD. As current treatments for IBD are not entirely effective, the pharmacological inhibition of NOX is an unexplored avenue that could provide a potential therapeutic target for the treatment of this disease.
Export Options
About this article
Cite this article as:
Lam Giang, Apostolopoulos Vasso, Zulli Anthony and Nurgali Kulmira, NADPH Oxidases and Inflammatory Bowel Disease, Current Medicinal Chemistry 2015; 22 (17) . https://dx.doi.org/10.2174/0929867322666150416095114
DOI https://dx.doi.org/10.2174/0929867322666150416095114 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Osteopontin Tissue Level as a Breast Cancer Biomarker in Females After Mastectomy Measured by the Capillary Gel Electrophoresis Technique
Combinatorial Chemistry & High Throughput Screening ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets Colon Targeted Liposomal Systems (CTLS): Theranostic Potential
Current Molecular Medicine A Review on the Molecular Mechanisms Involved in the Placental Barrier for Drugs
Current Drug Delivery Targeted Strategies in the Treatment of Primary Gastric Lymphomas: From Rituximab to Recent Insights into Potential New Drugs
Current Medicinal Chemistry Omega-3 Fatty Acids and their Role in Central Nervous System - A Review
Current Medicinal Chemistry Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies
Current Pharmaceutical Design Nanoparticles Based on Plasma Proteins for Drug Delivery Applications
Current Pharmaceutical Design Insights into Angiogenesis in Non-Small Cell Lung Cancer: Molecular Mechanisms, Polymorphic Genes, and Targeted Therapies
Recent Patents on Anti-Cancer Drug Discovery Fused Xanthone Derivatives as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Advances and Challenges in the Use of Nanoparticles to Optimize PK/PD Interactions of Combined Anti-Cancer Therapies
Current Drug Metabolism HIF-1α Modulates Energy Metabolism in Cancer Cells by Inducing Over-Expression of Specific Glycolytic Isoforms
Mini-Reviews in Medicinal Chemistry Novel Mechanisms of Anticancer Activities of Green Tea Component Epigallocatechin- 3-Gallate
Anti-Cancer Agents in Medicinal Chemistry Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics
Current Drug Delivery Oral Controlled Delivery of Natural Compounds Using Food-Grade Polymer Microparticles
Current Nutraceuticals The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors
Current Cancer Drug Targets Molecular Farming of Pharmaceutical Proteins Using Plant Suspension Cell and Tissue Cultures
Current Pharmaceutical Design Development of Focal Adhesion Kinase Inhibitors in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Retraction Notice: Protein Identification in Sub Proteome Fractions of Breast Cancer Cells by OFFGEL-IEF and iTRAQ Labeling
Current Proteomics E-Cadherin Upregulation as a Therapeutic Goal in Cancer Treatment
Mini-Reviews in Medicinal Chemistry